I've Just Been Diagnosed with Rheumatoid Arthritis — What Now?

Waking up with joint pain, stiffness, and swelling every day — and then getting a diagnosis that explains it — is a complicated moment. There is relief in having a name for what's been happening. There may also be fear about what this means for your future: your work, your independence, your quality of life.

Here is what decades of research have delivered: rheumatoid arthritis is now one of the most manageable chronic conditions in medicine. The majority of people diagnosed and treated early reach low disease activity or remission. The picture is very different from what it was twenty years ago.

What to Do Right Now: Five Steps

Step 1 — Start treatment as early as possible

In RA, time is joints. Every month of uncontrolled inflammation is a month of potential cartilage erosion and joint damage. The treatment goal — low disease activity or remission — is achievable but is much easier to reach when treatment starts early.

If your GP has made the diagnosis, ask for an urgent referral to a rheumatologist. If you are already seeing a rheumatologist, confirm that methotrexate has been prescribed (or that there is a reason it hasn't).

Step 2 — Understand your starting medication: methotrexate

Methotrexate (MTX) is the anchor drug in RA management worldwide and in South Africa. It is inexpensive, highly effective, and well-studied. It takes 6–12 weeks to work properly, so don't judge its effect in the first month.

You'll take it once a week (not daily — this is important; daily MTX dosing is a medication error). Your doctor will also prescribe folic acid on the other six days to prevent mouth sores and protect your liver.

MTX requires monthly blood monitoring in the first few months: a full blood count and liver function tests. Once stable, this drops to every three months.

Step 3 — Register for CDL benefits

Contact your medical scheme and register rheumatoid arthritis as a Chronic Disease List (CDL) condition. This unlocks dedicated chronic benefits that fund your medications (csDMARDs), rheumatologist consultations, and monitoring bloods. Your GP or rheumatologist should complete the CDL registration form.

CDL-funded medications include: methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. These four medications, used in combination, cost R150–650/month total and are fully scheme-funded.

Step 4 — Understand the treat-to-target approach

Your rheumatologist will assess your disease activity at every visit using a score called DAS28 (Disease Activity Score). The target is DAS28 below 2.6 (remission) or below 3.2 (low disease activity). If you're not at target at 3 months, the approach changes — medication is added, combined, or switched.

This is called treat-to-target. It is the global standard and the approach used in South Africa's 2024 SARAA guidelines. Understanding this helps you be an active participant in your care, not just a passenger.

Step 5 — Know where the escalation pathway goes (before you need it)

Most people with RA are well-controlled on csDMARDs — methotrexate and combinations. Some people, after adequate trials of combination csDMARD therapy, need to step up to biological therapy (biologic DMARDs) or JAK inhibitors.

If this happens, the process in South Africa involves: rheumatologist referral to the SARAA Biologics Advisory Peer Review Panel → SARAA BAPRP approval → scheme exceptional needs authorisation. It takes weeks to months. Knowing this process exists means you won't be surprised by it.

Your Most Important Questions, Answered

Will I have pain every day for the rest of my life? Not necessarily. The goal of treatment is remission — no active inflammation, no joint destruction, and for most people, very little or no daily pain. Many patients achieve remission on methotrexate within 6–12 months.

Can I still work? Yes, in most cases. RA that is well-controlled on treatment does not preclude employment. For jobs involving physical labour or fine motor tasks, there may be limitations during flares. Early aggressive treatment dramatically reduces long-term disability risk.

What if I can't tolerate methotrexate? A significant minority of patients have side effects that prevent them tolerating MTX (nausea, fatigue, mouth sores, liver changes). Switching to subcutaneous injection (instead of oral) reduces side effects for many. Leflunomide is a well-established alternative. Talk to your rheumatologist — the first drug isn't always the right drug.

What will this cost me? On csDMARDs: minimal. MTX + folic acid + HCQ or SSZ = R200–500/month, fully CDL-funded. Rheumatologist visits and blood tests: CDL-funded. The cost escalation point is biologic therapy — adalimumab biosimilar runs ~R60,000/year, originator ~R108,000/year.

What about exercise? Exercise is recommended — and not just permitted. It improves joint function, reduces fatigue, supports mental health, and protects against the cardiovascular risk that comes with RA. During a flare, low-impact activity (swimming, cycling). Between flares: resistance training to support joints.

The Next Three Months

Your Scheme Coverage for RA

csDMARDs are fully CDL-funded. The critical scheme variable for RA is biologic formulary policy — which biologics the scheme covers, at what level of exceptional needs, and whether they mandate biosimilar-first (adalimumab biosimilar before originator). This is worth checking now, even if you're well-controlled on csDMARDs.

Joint replacement surgery is the other scheme variable. If you reach the stage of needing a total knee or hip replacement, your scheme's orthopaedic surgery rate and any applicable sub-limits determine your out-of-pocket exposure.

Ready to check how your scheme covers RA, including the biologic pathway? Run your AURA check